Incyte Corp. (INCY) disclosed Monday morning that it was informed last week of a case of progressive multifocal leukoencephalopathy in a 75 year old male patient from the United Kingdom with myelofibrosis treated with ruxolitinib.
Incyte gapped open sharply lower Monday, but recovered some ground in early trade, before settling into a range. The stock closed down by 1.05 at $23.79, with volume at a 7-month high.
For comments and feedback: editorial@rttnews.com